Workflow
Logic
icon
Search documents
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Globenewswire· 2025-05-22 21:05
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that results from the Company’s positive phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with intermediate-to-high-risk localized prostate cancer will be presented at the 2025 American Society of Clinical Oncology (ASCO) ...
Jasper Therapeutics (JSPR) 2025 Conference Transcript
2025-05-21 16:00
Summary of Jasper Therapeutics (JSPR) Conference Call Company Overview - Jasper Therapeutics focuses on mast cell-mediated diseases, with its lead asset being briquelimab, a monoclonal antibody targeting c-KIT on mast cells [2][3] Core Points and Arguments Mechanism of Action - Briquelimab targets c-KIT, which is crucial for mast cell survival. Inhibition leads to mast cell apoptosis, making it a clean mechanism for treating related diseases [3][4][5] Clinical Trials and Data - The BEACON study is a Phase 1/2 trial exploring optimal dosing of briquelimab in chronic spontaneous urticaria (CSU) [6] - Initial data showed a rapid onset of clinical relief, with complete responses ranging from 50% to 100% at the 240 mg dose level, durable for eight weeks [10][12] - The study tested doses from 10 mg to 240 mg, with a half-life of approximately nine days for briquelimab [7][9] Safety Profile - The safety profile of briquelimab appears favorable, with no unexpected adverse events reported. Most c-KIT related adverse events were mild and transient [21][24] - Neutropenia concerns were addressed, indicating that stem cells remain viable despite c-KIT inhibition [22][24] Future Data and Expectations - Upcoming data from the BEACON study is expected in mid-2025, which will help differentiate briquelimab from competitors like Barzolumab [25][26] - The company plans to initiate a Phase 2b adaptive clinical trial by the end of 2025 [27] Competitive Landscape - The approval of Dupixent is seen as beneficial for educating dermatologists about biologics in CSU, but briquelimab and Barzolumab are the only therapies that deplete mast cells [39][40] - Briquelimab is positioned as a potential therapy of choice in the CSU setting due to its unique mechanism [41] Broader Pipeline - Jasper Therapeutics is also exploring briquelimab for mild to moderate asthma, with data expected in the second half of 2025 [42][43] - The company is considering additional indications, targeting diseases that are mast cell-mediated [42] Important but Overlooked Content - The BEACON study's small sample size may affect the interpretation of data, particularly regarding the complete response rates [12][18] - The potential for misdiagnosis in patients with CSU was highlighted, indicating the need for careful patient selection [19] This summary encapsulates the key points discussed during the conference call, providing insights into Jasper Therapeutics' current status, future plans, and competitive positioning in the market.
Bioceres Crop Solutions (BIOX) - 2025 Q3 - Earnings Call Transcript
2025-05-21 13:32
Bioceres Crop Solutions (BIOX) Q3 2025 Earnings Call May 21, 2025 08:30 AM ET Company Participants Paula Savanti - Head, IRFederico Trucco - Executive Chairman & CEOEnrique López Lecube - CFO & Executive DirectorMilen Marinov - CCOKristen Owen - Managing DirectorAustin Moeller - Director - Equity Research Conference Call Participants Ben Klieve - Senior Equity Research AnalystSteve Byrne - Senior Research AnalystKemp Dolliver - Director - Research & Senior Analyst Operator It's now my pleasure to hand over ...
Upstream Bio Appoints Stacy Price as Chief Technology Officer
Globenewswire· 2025-05-20 11:00
About Upstream Bio Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. ...
Is Holding Liberty Energy Stock the Best Strategy for Now?
ZACKS· 2025-05-19 13:36
Liberty Energy Inc. (LBRT) is a key name in the oil and gas field services sub-industry, known for its expertise in hydraulic fracturing. This technique is important in the oil and gas sector for extracting oil and gas from tough underground rock formations, like shale. Liberty supports this process by offering a full set of services, everything from delivering proppant (a key material used in fracking) to sand mining, on-site fueling and data analytics to help companies operate more efficiently.The company ...
李嘉诚预言说中了!我国手握“多套房”的家庭,或将注定4个结果
Sou Hu Cai Jing· 2025-05-19 09:57
手里捏着多套房的家庭,未来可能要面对的四个残酷现实。 这可不是我危言耸听,2025年的数据摆在这儿: 重点城市二手房挂牌量连续两个月环比回升,2月突破200.6万套,同比虽下降11.6%,但环比增长 2.01%17; 三四线城市更惨,南阳这类城市的二手房挂牌量比2020年暴增210%,平均成交周期拉长到108天,几乎 成了"不能动的资产"。 更扎心的是,全国100个重点城市二手房价同比下跌5.15%,一线城市环比跌0.24%,三四线同比跌幅甚 至达4.48%。 这些数据比李嘉诚当年说"中国房产过剩"时还要触目惊心,咱们今天就用2025年的最新数据,拆解多套 房家庭的四大困局。 更隐痛的是房屋老化,湖南衡阳一15年房龄的电梯房,换根钢丝绳每户摊8000元,而小区房价才4500 元/㎡,业主直呼"修电梯的钱够买1.7㎡房子"。 北京朝阳某高端小区,三套房的物业费一年吃掉15万租金,这还没算房贷利息和折旧损失。 第三个雷区是法拍房大爆发,割肉都难止损。 第一个逃不掉的结果——二手房根本卖不动,尤其是三四线。我团队扒了麟评研究院的数据, 2025年重点城市二手房去化周期从2023年的20个月以上降到18个月,看似好转 ...
Sword Group: Notification of Threshold Crossing
Globenewswire· 2025-05-15 19:40
By letter received on May 13, 2025, the simplified joint-stock company Indépendance AM (20 avenue Franklin D. Roosevelt, 75008 Paris), acting on behalf of funds under its management, declared that on May 8, 2025, it had crossed upwards the thresholds of 5% of the share capital and voting rights of Sword Group. It stated that it holds, on behalf of the aforementioned funds, 512,929 Sword Group shares, representing the same number of voting rights, i.e., 5.37% of the company’s share capital and voting rights ...
Tectonic Therapeutic (TECX) 2025 Conference Transcript
2025-05-15 17:20
Tectonic Therapeutic (TECX) 2025 Conference May 15, 2025 12:20 PM ET Speaker0 Hey, everyone. Good morning, and welcome to day three of the twenty twenty five Bank of America Healthcare Conference. And thanks for joining this session with Tectonic Therapeutics. My name is Alex Stranahan. I'm senior biotech analyst at Bank of America. And I'm pleased to introduce Elise Raisin, president and CEO of Tectonic. She'll be running through some slides and going over the company. So with that, Elise, over to you. Spe ...
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
Globenewswire· 2025-05-15 13:00
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published positive data from its global Phase 2 study supporting potential of rademikibart as a novel biologic treatment for patients with asthma and Type 2 inflammation Strong balance sheet with cash runway into 2027 through key clinical catalysts SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Connect Bi ...
Werewolf Therapeutics (HOWL) 2025 Conference Transcript
2025-05-14 23:17
Summary of Werewolf Therapeutics Conference Call Company Overview - Werewolf Therapeutics is a clinical stage biopharmaceutical company focused on developing conditionally activated biologics for cancer and other serious diseases. The company has engineered a pipeline of cytokine prodrugs, referred to as endokines, to address therapeutic index challenges associated with potent biologics [2][3] Core Programs - The lead endokine programs include: - WTX-124 (an interleukin-2 endokine) - WTX-330 (an interleukin-12 endokine) - The company has also developed T cell engagers called inducers, designed to address therapeutic index challenges of T cell engagers [3][19] Clinical Data and Efficacy - WTX-124 has completed dose escalation for both monotherapy and combination therapy with pembrolizumab, with a determined dose of 18 mg delivered IV every two weeks [5][6] - Expansion arms are open for indications including: - Cutaneous melanoma - Renal cell carcinoma - Cutaneous squamous cell carcinoma, where a patient achieved a complete response after failing standard treatment [6][7] - The company aims for an overall response rate above 20% for monotherapy and higher for combination therapy, with enrollment progressing well [11][12] Safety Profile - The safety profile of WTX-124 has shown no hallmark toxicities associated with high-dose IL-2, allowing for outpatient delivery to a broad patient population [9][10] Regulatory Pathway - The company plans to present data to the FDA in the coming quarters, seeking insights on both monotherapy and combination data for potential registration [13][14] Future Expectations - The company anticipates presenting updated interim data in Q4 2025, with a focus on both efficacy and safety metrics [9][22] - For WTX-330, the company has completed a first-in-human trial, showing a good safety profile and antitumor activity, with plans for further studies [16][17] Inducers Platform - The inducers platform aims to mask immune cell engagement to reduce cytokine release syndrome, enhancing the therapeutic index of T cell engagers [19][20] - The company plans to announce a development candidate for the inducers platform imminently [22] Conclusion - Werewolf Therapeutics is positioned for significant developments in the coming months, with a robust pipeline and promising clinical data that could lead to regulatory advancements and potential market opportunities [24][25]